232 related articles for article (PubMed ID: 32055439)
1. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease：A case report.
Kagawa H; Tsujino K; Yamamoto Y; Iwai A; Hara R; Matsuki T; Fukushima K; Oshitani Y; Yoshimura K; Miki M; Miki K; Kitada S; Mori M; Kida H
Respir Med Case Rep; 2020; 29():101016. PubMed ID: 32055439
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
[TBL] [Abstract][Full Text] [Related]
3. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
[TBL] [Abstract][Full Text] [Related]
4. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
McPherson M; Economidou S; Liampas A; Zis P; Parperis K
Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
[TBL] [Abstract][Full Text] [Related]
5. A case of clinically amyopathic dermatomyositis that was refractory to intensive immunosuppressive therapy including tofacitinib, but successfully treated with plasma exchange therapy.
Hiraoka D; Ishizaki J; Horie K; Matsumoto T; Suemori K; Takenaka K; Hasegawa H
Mod Rheumatol Case Rep; 2022 Jun; 6(2):194-198. PubMed ID: 34984465
[TBL] [Abstract][Full Text] [Related]
6. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
8. Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia: Two case reports.
Ishiwari M; Togashi Y; Takoi H; Kikuchi R; Kawagoe J; Toriyama K; Tanaka A; Nagotomo Y; Kinoshita H; Kono Y; Abe S
Respir Med Case Rep; 2021; 33():101464. PubMed ID: 34401300
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
10. Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.
Yamazoe M; Takeda K; Nagano Y; Nagano K; Kato K; Inoue T; Horiuchi K; Kamada K
Intern Med; 2024 Feb; ():. PubMed ID: 38346740
[TBL] [Abstract][Full Text] [Related]
11. Early Initiation of Plasma Exchange Therapy for Anti-MDA5
Sasaki N; Nakagome Y; Kojima A; Shimura K; Ishii A; Sugiyama M; Izumi Y; Hirano K; Kurabayashi T; Hosono Y; Yamada C; Sato S
Intern Med; 2024 Jan; 63(2):213-219. PubMed ID: 37225493
[TBL] [Abstract][Full Text] [Related]
12. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.
Aoyama J; Hayashi H; Yajima C; Takoi H; Tanaka T; Kashiwada T; Kokuho N; Terasaki Y; Nishikawa A; Gono T; Kuwana M; Saito Y; Abe S; Seike M; Gemma A
Respir Med Case Rep; 2019; 26():193-196. PubMed ID: 30723666
[TBL] [Abstract][Full Text] [Related]
13. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
[TBL] [Abstract][Full Text] [Related]
15. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
16. Management of Myositis-Associated Interstitial Lung Disease.
Fujisawa T
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.
Watanabe T; Taniguchi M; Ogura S; Asou M; Takayanagi S; Sokai Y; Tsuji Y; Mori KP; Endo T; Nakajima T; Imura Y; Tsukamoto T
Ther Apher Dial; 2024 Jun; 28(3):432-441. PubMed ID: 38225794
[TBL] [Abstract][Full Text] [Related]
18. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Ishikawa Y; Kasuya T; Fujiwara M; Kita Y
Medicine (Baltimore); 2020 Sep; 99(37):e21943. PubMed ID: 32925726
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
